• Je něco špatně v tomto záznamu ?

Defibrillation testing and clinical outcomes after implantable cardioverter-defibrillator implantation in patients in atrial fibrillation at the time of implant: An analysis from the SIMPLE trial

S. Bogdan, M. Glikson, SJ. Connolly, J. Wang, SH. Hohnloser, U. Appl, J. Neuzener, P. Mabo, X. Vinolas, F. Gadler, L. van Erven, J. Kautzner, B. Meeks, J. Pogue, JS. Healey,

. 2019 ; 16 (1) : 83-90. [pub] 20180729

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025976

BACKGROUND: The Shockless IMPLant Evaluation (SIMPLE) trial showed that defibrillation testing (DT) at the time of implantable cardioverter-defibrillator (ICD) implant did not improve shock efficacy or reduce mortality. There are no data regarding the risk of complications, including stroke, among patients with atrial fibrillation (AF) who undergo DT. OBJECTIVE: The purpose of this prospectively planned substudy of SIMPLE was to evaluate the effect of DT vs no DT on clinical outcomes among patients with AF. METHODS: We compared efficacy (failed appropriate shock/arrhythmic death) and safety between patients who had AF on their immediate preprocedural ECG to the rest of the study patients. Then among patients with AF we compared these outcomes between patients randomized to DT vs no DT. RESULTS: Of the 2500 patients enrolled in SIMPLE, 251 (10%) were in AF immediately before ICD implant. AF patients had an increased risk of failed appropriate shock/arrhythmic death (adjusted hazard ratio [HR] 1.64; 95% confidence interval [CI] 1.13-2.39; P = .009) and higher all-cause mortality (adjusted HR 1.58; 95% CI 1.2-2.08; P = .001). Among AF patients, perioperative complications and stroke did not significantly differ between DT vs no-DT groups (9.2% vs 5.4%; P = .2; and 1.7% vs 1.5%; P >.999, respectively). Failed appropriate shock or arrhythmic death occurred in 35 of 251 AF patients (14%), and the no-DT group proved not inferior to the DT group (HR 0.58; 95% CI 0.30-1.15; Pnoninferiority = .006). CONCLUSION: ICD recipients with AF are at increased risk for adverse outcomes; however, DT does not improve arrhythmic survival or shock efficacy. There is no evidence that DT increased the occurrence of perioperative stroke.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025976
003      
CZ-PrNML
005      
20201222155546.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.hrthm.2018.07.030 $2 doi
035    __
$a (PubMed)30063996
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bogdan, Stefan $u Leviev Heart Center, Sheba Medical Center, Tel Hashomer, Israel.
245    10
$a Defibrillation testing and clinical outcomes after implantable cardioverter-defibrillator implantation in patients in atrial fibrillation at the time of implant: An analysis from the SIMPLE trial / $c S. Bogdan, M. Glikson, SJ. Connolly, J. Wang, SH. Hohnloser, U. Appl, J. Neuzener, P. Mabo, X. Vinolas, F. Gadler, L. van Erven, J. Kautzner, B. Meeks, J. Pogue, JS. Healey,
520    9_
$a BACKGROUND: The Shockless IMPLant Evaluation (SIMPLE) trial showed that defibrillation testing (DT) at the time of implantable cardioverter-defibrillator (ICD) implant did not improve shock efficacy or reduce mortality. There are no data regarding the risk of complications, including stroke, among patients with atrial fibrillation (AF) who undergo DT. OBJECTIVE: The purpose of this prospectively planned substudy of SIMPLE was to evaluate the effect of DT vs no DT on clinical outcomes among patients with AF. METHODS: We compared efficacy (failed appropriate shock/arrhythmic death) and safety between patients who had AF on their immediate preprocedural ECG to the rest of the study patients. Then among patients with AF we compared these outcomes between patients randomized to DT vs no DT. RESULTS: Of the 2500 patients enrolled in SIMPLE, 251 (10%) were in AF immediately before ICD implant. AF patients had an increased risk of failed appropriate shock/arrhythmic death (adjusted hazard ratio [HR] 1.64; 95% confidence interval [CI] 1.13-2.39; P = .009) and higher all-cause mortality (adjusted HR 1.58; 95% CI 1.2-2.08; P = .001). Among AF patients, perioperative complications and stroke did not significantly differ between DT vs no-DT groups (9.2% vs 5.4%; P = .2; and 1.7% vs 1.5%; P >.999, respectively). Failed appropriate shock or arrhythmic death occurred in 35 of 251 AF patients (14%), and the no-DT group proved not inferior to the DT group (HR 0.58; 95% CI 0.30-1.15; Pnoninferiority = .006). CONCLUSION: ICD recipients with AF are at increased risk for adverse outcomes; however, DT does not improve arrhythmic survival or shock efficacy. There is no evidence that DT increased the occurrence of perioperative stroke.
650    _2
$a senioři $7 D000368
650    _2
$a fibrilace síní $x mortalita $x patofyziologie $x terapie $7 D001281
650    12
$a defibrilátory implantabilní $7 D017147
650    12
$a elektrokardiografie $7 D004562
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a převodní systém srdeční $x patofyziologie $7 D006329
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a míra přežití $x trendy $7 D015996
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Glikson, Michael $u Leviev Heart Center, Sheba Medical Center, Tel Hashomer, Israel.
700    1_
$a Connolly, Stuart J $u Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
700    1_
$a Wang, Jia $u Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
700    1_
$a Hohnloser, Stefan H $u JW Goethe University, Frankfurt, Germany.
700    1_
$a Appl, Ursula $u Boston Scientific, Minneapolis, Minnesota, and Brussels, Belgium.
700    1_
$a Neuzener, Jorg $u Klinikum Kassel, Kassel, Germany.
700    1_
$a Mabo, Philippe $u Centre Hospitalier Universitaire, Rennes, France.
700    1_
$a Vinolas, Xavier $u Hospital de Santa Creu i Sant Pau, Barcelona, Spain.
700    1_
$a Gadler, Frederick $u Karolinska Institute, Stockholm, Sweden.
700    1_
$a van Erven, Lieselot $u Leiden University Medical Center, Leiden, The Netherlands.
700    1_
$a Kautzner, Josef $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Meeks, Brandi $u Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
700    1_
$a Pogue, Janice $u Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
700    1_
$a Healey, Jeff S $u Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada. Electronic address: Jeff.Healey@phri.ca.
773    0_
$w MED00156180 $t Heart rhythm $x 1556-3871 $g Roč. 16, č. 1 (2019), s. 83-90
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30063996 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155541 $b ABA008
999    __
$a ok $b bmc $g 1600121 $s 1116662
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 16 $c 1 $d 83-90 $e 20180729 $i 1556-3871 $m Heart rhythm $n Heart Rhythm $x MED00156180
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace